Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice?
McCormack
James P
JP
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada. jmccorma@interchange.ubc.ca
Allan
G Michael
GM
D000368:Aged; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000276:immunology / Q000517:prevention & control; D019317:Evidence-Based Medicine; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D011237:Predictive Value of Tests; D011743:Pyrimidines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D018570:Risk Assessment; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use; D016896:Treatment Outcome; D019564:Unnecessary Procedures
D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein